In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al
- PMID: 16320358
- DOI: 10.1002/art.21610
In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al
Comment on
-
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.Arthritis Rheum. 2005 Feb;52(2):501-13. doi: 10.1002/art.20858. Arthritis Rheum. 2005. PMID: 15693003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
